Exane Derivatives’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Exane Derivatives’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-87	Closed	-$4.69K	–	669
2017 Q4	$4.69K	Hold	87	–	–	﹤0.01%	430
2017 Q3	$4.96K	Hold	87	–	–	﹤0.01%	423
2017 Q2	$5.23K	Hold	87	–	–	﹤0.01%	429
2017 Q1	$4.74K	Buy	+87	New	+$4.29K	﹤0.01%	375

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Exane Derivatives's BIVV Position: Q1 2018 in Review

Exane Derivatives sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 87 shares — an estimated $4.69K sold.

Exane Derivatives first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $5.23K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Exane Derivatives reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Exane Derivatives sold 87 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $4.69K.
Exane Derivatives first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Exane Derivatives's Bioverativ Inc. Common Stock position peaked at $5.23K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Exane Derivatives's 13F filing for Q1 2018, filed 30 Apr 2018.